1. Home
  2. MYN vs CADL Comparison

MYN vs CADL Comparison

Compare MYN & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniYield New York Quality Fund Inc.

MYN

Blackrock MuniYield New York Quality Fund Inc.

HOLD

Current Price

$9.66

Market Cap

380.1M

Sector

Finance

ML Signal

HOLD

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$5.04

Market Cap

357.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYN
CADL
Founded
1992
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
380.1M
357.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MYN
CADL
Price
$9.66
$5.04
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$19.00
AVG Volume (30 Days)
170.4K
1.2M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
4.12%
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
N/A
$125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.13
$4.25
52 Week High
$10.26
$7.24

Technical Indicators

Market Signals
Indicator
MYN
CADL
Relative Strength Index (RSI) 39.85 49.25
Support Level $9.14 $4.58
Resistance Level $10.21 $5.42
Average True Range (ATR) 0.10 0.25
MACD -0.02 0.03
Stochastic Oscillator 43.40 70.00

Price Performance

Historical Comparison
MYN
CADL

About MYN Blackrock MuniYield New York Quality Fund Inc.

Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: